The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | The progress of CLL research: towards targeted therapy
Kostas Stamatopoulos, MD, PhD from CERTH Institute of Applied Biosciences, Thessaloniki, Greece discusses the progress of research in chronic lymphocytic leukemia (CLL). Dr Stamatopoulos points out how novel drugs are different from traditional chemotherapy or immunotherapy as they target fundamental processes, which can translate into better response rates and in future, a cure.
Recorded at the at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
